The last 12 months have seen the neurodegenerative community make numerous strides into understanding these disorders. However, 2017 has been a rocky journey, particularly so for Alzheimer’s Disease, adding weight to the growing concern as to whether there is a fundamental flaw in our understanding of the disease, its mechanisms or our path to targeting it.
As Program Director & Researcher for the 6th Annual World CNS Summit, I invite you to join a truly diverse group of professionals from biopharmaceutical, technology and academic institutions, in paving the path forward for neurodegenerative therapeutics.
This year we have refined the theme of the meeting to ‘transforming discovery and translational research into disease modifying therapeutics’ to exemplify the vast opportunities that remain at our fingertips.
Focused specifically on the translational barriers in neurodegenerative R&D, this is an opportunity to look beyond A-Beta Tauthe and other classical targets of neurodegeneration. It will highlight foundational research into promising targets, such as neuroinflammation, and the strategic approaches to modulate these.
Join over 60 biopharmaceutical organizations and 100 experts in harnessing new innovations, to tackle the challenges at the crux of your pipeline. Redefine the use of preclinical models of neurodegeneration, enhance their application in your translational research and advance translational biomarker discovery - from target engagement to disease progression.
To find out more about agenda topics, speakers and fees, please visit the event website: http://bit.ly/2ACp7iX. We offer a special discounted rate for small biotechs to attend. Full information and eligibility criteria can be found on the website.
As Program Director & Researcher for the 6th Annual World CNS Summit, I invite you to join a truly diverse group of professionals from biopharmaceutical, technology and academic institutions, in paving the path forward for neurodegenerative therapeutics.
This year we have refined the theme of the meeting to ‘transforming discovery and translational research into disease modifying therapeutics’ to exemplify the vast opportunities that remain at our fingertips.
Focused specifically on the translational barriers in neurodegenerative R&D, this is an opportunity to look beyond A-Beta Tauthe and other classical targets of neurodegeneration. It will highlight foundational research into promising targets, such as neuroinflammation, and the strategic approaches to modulate these.
Join over 60 biopharmaceutical organizations and 100 experts in harnessing new innovations, to tackle the challenges at the crux of your pipeline. Redefine the use of preclinical models of neurodegeneration, enhance their application in your translational research and advance translational biomarker discovery - from target engagement to disease progression.
To find out more about agenda topics, speakers and fees, please visit the event website: http://bit.ly/2ACp7iX. We offer a special discounted rate for small biotechs to attend. Full information and eligibility criteria can be found on the website.
